HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D
- PMID: 18097044
- DOI: 10.4049/jimmunol.180.1.426
HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D
Abstract
Evidence obtained from both animal models and humans suggests that T cells specific for HSV-1 and HSV-2 glycoprotein D (gD) contribute to protective immunity against herpes infection. However, knowledge of gD-specific human T cell responses is limited to CD4+ T cell epitopes, with no CD8+ T cell epitopes identified to date. In this study, we screened the HSV-1 gD amino acid sequence for HLA-A*0201-restricted epitopes using several predictive computational algorithms and identified 10 high probability CD8+ T cell epitopes. Synthetic peptides corresponding to four of these epitopes, each nine to 10 amino acids in length, exhibited high-affinity binding in vitro to purified human HLA-A*0201 molecules. Three of these four peptide epitopes, gD53-61, gD70-78, and gD278-286, significantly stabilized HLA-A*0201 molecules on T2 cell lines and are highly conserved among and between HSV-1 and HSV-2 strains. Consistent with this, in 33 sequentially studied HLA-A*0201-positive, HSV-1-seropositive, and/or HSV-2-seropositive healthy individuals, the most frequent and robust CD8+ T cell responses, assessed by IFN-gamma ELISPOT, CD107a/b cytotoxic degranulation, and tetramer assays, were directed mainly against gD53-61, gD70-78, and gD278-286 epitopes. In addition, CD8+ T cell lines generated by gD53-61, gD70-78, and gD278-286 peptides recognized infected target cells expressing native gD. Lastly, CD8+ T cell responses specific to gD53-61, gD70-78, and gD278-286 epitopes were induced in HLA-A*0201 transgenic mice following ocular or genital infection with either HSV-1 or HSV-2. The functional gD CD8+ T cell epitopes described herein are potentially important components of clinical immunotherapeutic and immunoprophylactic herpes vaccines.
Similar articles
-
Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.J Virol. 2017 Jan 3;91(2):e01793-16. doi: 10.1128/JVI.01793-16. Print 2017 Jan 15. J Virol. 2017. PMID: 27847359 Free PMC article.
-
Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.J Immunol. 2013 Nov 15;191(10):5124-38. doi: 10.4049/jimmunol.1301415. Epub 2013 Oct 7. J Immunol. 2013. PMID: 24101547 Free PMC article.
-
HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgenic mice against ocular herpes.J Immunol. 2015 Mar 1;194(5):2232-48. doi: 10.4049/jimmunol.1402606. Epub 2015 Jan 23. J Immunol. 2015. PMID: 25617474 Free PMC article.
-
The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.Vaccine. 2014 Nov 28;32(50):6733-45. doi: 10.1016/j.vaccine.2014.10.002. Epub 2014 Oct 16. Vaccine. 2014. PMID: 25446827 Free PMC article. Review.
-
Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?Vaccine. 2011 Aug 11;29(35):5824-36. doi: 10.1016/j.vaccine.2011.06.083. Epub 2011 Jun 28. Vaccine. 2011. PMID: 21718746 Free PMC article. Review.
Cited by
-
Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107+ CD8+ T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect against Ocular Herpes Challenge.J Virol. 2018 Jul 31;92(16):e00535-18. doi: 10.1128/JVI.00535-18. Print 2018 Aug 15. J Virol. 2018. PMID: 29899087 Free PMC article.
-
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.Future Virol. 2012 Apr 1;7(4):371-378. doi: 10.2217/fvl.12.22. Future Virol. 2012. PMID: 22701511 Free PMC article.
-
Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.Clin Vaccine Immunol. 2009 May;16(5):699-705. doi: 10.1128/CVI.00370-08. Epub 2009 Mar 11. Clin Vaccine Immunol. 2009. PMID: 19279167 Free PMC article.
-
Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.Clin Dev Immunol. 2012;2012:149135. doi: 10.1155/2012/149135. Epub 2012 Dec 24. Clin Dev Immunol. 2012. PMID: 23320014 Free PMC article. Review.
-
Human Epitopes Identified from Herpes Simplex Virus Tegument Protein VP11/12 (UL46) Recall Multifunctional Effector Memory CD4+ TEM Cells in Asymptomatic Individuals and Protect from Ocular Herpes Infection and Disease in "Humanized" HLA-DR Transgenic Mice.J Virol. 2020 Mar 17;94(7):e01991-19. doi: 10.1128/JVI.01991-19. Print 2020 Mar 17. J Virol. 2020. PMID: 31915285 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials